title: Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
abstract: BACKGROUND
  Fabry disease (FD) is a lysosomal storage disorder resulting in progressive nervous system, kidney and heart disease. Enzyme replacement therapy (ERT) may halt or attenuate disease progression. Since administration is burdensome and expensive, appropriate use is mandatory. We aimed to define European consensus recommendations for the initiation and cessation of ERT in patients with FD.
  
  
  METHODS
  A Delphi procedure was conducted with an online survey (n = 28) and a meeting (n = 15). Patient organization representatives were present at the meeting to give their views. Recommendations were accepted with ≥75% agreement and no disagreement.
  
  
  RESULTS
  For classically affected males, consensus was achieved that ERT is recommended as soon as there are early clinical signs of kidney, heart or brain involvement, but may be considered in patients of ≥16 years in the absence of clinical signs or symptoms of organ involvement. Classically affected females and males with non-classical FD should be treated as soon as there are early clinical signs of kidney, heart or brain involvement, while treatment may be considered in females with non-classical FD with early clinical signs that are considered to be due to FD. Consensus was achieved that treatment should not be withheld from patients with severe renal insufficiency (GFR < 45 ml/min/1.73 m(2)) and from those on dialysis or with cognitive decline, but carefully considered on an individual basis. Stopping ERT may be considered in patients with end stage FD or other co-morbidities, leading to a life expectancy of <1 year. In those with cognitive decline of any cause, or lack of response for 1 year when the sole indication for ERT is neuropathic pain, stopping ERT may be considered. Also, in patients with end stage renal disease, without an option for renal transplantation, in combination with advanced heart failure (NYHA class IV), cessation of ERT should be considered. ERT in patients who are non-compliant or fail to attend regularly at visits should be stopped.
  
  
  CONCLUSIONS
  The recommendations can be used as a benchmark for initiation and cessation of ERT, although final decisions should be made on an individual basis. Future collaborative efforts are needed for optimization of these recommendations.
authors.affiliation: Department of Internal Medicine, Division Endocrinology and Metabolism, Academic Medical Center, PO Box 22660, Amsterdam, 1100 DD, The Netherlands. m.biegstraaten@amc.uva.nl.
authors.forename: Marieke
authors.initials: M
authors.lastname: Biegstraaten
authors.affiliation: Biomedical Center, University of Iceland and Landspitali University Hospital, Reykjavík, Iceland. reynirar@landspitali.is.
authors.forename: Reynir
authors.initials: R
authors.lastname: Arngrímsson
authors.affiliation: Center of Molecular Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. frederic.barbey@chuv.ch.
authors.forename: Frederic
authors.initials: F
authors.lastname: Barbey
authors.affiliation: Fabry International Network (FIN), Amersham, UK. lut@boks.be.
authors.forename: Lut
authors.initials: L
authors.lastname: Boks
authors.affiliation: Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy. francocecchi337@gmail.com.
authors.forename: Franco
authors.initials: F
authors.lastname: Cecchi
authors.affiliation: Department of Medicine, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK. patrick.deegan@addenbrookes.nhs.uk.
authors.forename: Patrick B
authors.initials: PB
authors.lastname: Deegan
authors.affiliation: Department of Medical Endocrinology, Copenhagen University Hospital, Copenhagen, Denmark. Ulla.Feldt-Rasmussen@regionh.dk.
authors.forename: Ulla
authors.initials: U
authors.lastname: Feldt-Rasmussen
authors.affiliation: Department of Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Tarekegn.Geberhiwot@uhb.nhs.uk.
authors.forename: Tarekegn
authors.initials: T
authors.lastname: Geberhiwot
authors.affiliation: Division of Medical Genetics, University of Versailles, Montigny, France. dominique.germain@rpc.aphp.fr.
authors.forename: Dominique P
authors.initials: DP
authors.lastname: Germain
authors.affiliation: Department of Adult Inherited Metabolic Disorders, Manchester Academic Health Science Centre, Manchester, UK. Chris.Hendriksz@srft.nhs.uk.
authors.forename: Chris
authors.initials: C
authors.lastname: Hendriksz
authors.affiliation: Department of Haematology, Lysosomal Storage Disorders Unit, Royal Free Hospital, University College London, London, UK. rmgvdah@ucl.ac.uk.
authors.forename: Derralynn A
authors.initials: DA
authors.lastname: Hughes
authors.affiliation: Division of Medicine, Turku University Hospital, Turku, Finland. Ilkka.Kantola@tyks.fi.
authors.forename: Ilkka
authors.initials: I
authors.lastname: Kantola
authors.affiliation: Villa Metabolica, Centre for Paediatric and Adolescent Medicine, Mainz, Germany. Nesrin.Karabul@unimedizin-mainz.de.
authors.forename: Nesrin
authors.initials: N
authors.lastname: Karabul
authors.affiliation: Fabry International Network (FIN), Amersham, UK. C.Lavery@mpssociety.org.uk.
authors.forename: Christine
authors.initials: C
authors.lastname: Lavery
authors.affiliation: Department of Internal Medicine, Division Endocrinology and Metabolism, Academic Medical Center, PO Box 22660, Amsterdam, 1100 DD, The Netherlands. g.e.linthorst@amc.uva.nl.
authors.forename: Gabor E
authors.initials: GE
authors.lastname: Linthorst
authors.affiliation: Department of Haematology, Lysosomal Storage Disorders Unit, Royal Free Hospital, University College London, London, UK. atul.mehta1@nhs.net.
authors.forename: Atul
authors.initials: A
authors.lastname: Mehta
authors.affiliation: Fabry Support and Information Group the Netherlands (FSIGN), Oosterwolde, the Netherlands. erica@fabry.nl.
authors.forename: Erica
authors.initials: E
authors.lastname: van de Mheen
authors.affiliation: Department of Genetics, University of Porto & São João Hospital Centre, Porto, Portugal. jpo@med.up.pt.
authors.forename: João P
authors.initials: JP
authors.lastname: Oliveira
authors.affiliation: Rare Metabolic Diseases Unit, Paediatric Clinic, San Gerardo University Hospital, Monza, Italy. rossella.parini@unimib.it.
authors.forename: Rossella
authors.initials: R
authors.lastname: Parini
authors.affiliation: Lysosomal Disorders Unit, Institute of Immunity and Transplantation, Royal Free Hospital, London, UK. uma.ramaswami@nhs.net.
authors.forename: Uma
authors.initials: U
authors.lastname: Ramaswami
authors.affiliation: Department of Internal Medicine IV, Division Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria. michael.rudnicki@i-med.ac.at.
authors.forename: Michael
authors.initials: M
authors.lastname: Rudnicki
authors.affiliation: Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. a.serra@gmx.ch.
authors.forename: Andreas
authors.initials: A
authors.lastname: Serra
authors.affiliation: Department of Neurology, University of Würzburg, Würzburg, Germany. sommer@uni-wuerzburg.de.
authors.forename: Claudia
authors.initials: C
authors.lastname: Sommer
authors.affiliation: Department of Medicine III, Division Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria. Gere.Sunder-Plassmann@meduniwien.ac.at.
authors.forename: Gere
authors.initials: G
authors.lastname: Sunder-Plassmann
authors.affiliation: Department of Medicine, Haukeland University Hospital and Department of Clinical Medicine, University of Bergen, Bergen, Norway. Einar.Svarstad@k1.uib.no.
authors.forename: Einar
authors.initials: E
authors.lastname: Svarstad
authors.affiliation: Fabry Support and Information Group the Netherlands (FSIGN), Oosterwolde, the Netherlands. asweeb@xs4all.nl.
authors.forename: Annelies
authors.initials: A
authors.lastname: Sweeb
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Ghent University Hospital, Ghent, Belgium. wim.terryn@gmail.com.
authors.forename: Wim
authors.initials: W
authors.lastname: Terryn
authors.affiliation: Department of Paediatrics, Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland. atylki@op.pl.
authors.forename: Anna
authors.initials: A
authors.lastname: Tylki-Szymanska
authors.affiliation: Clinical Trial Unit/Department of Paediatrics, Haukeland University Hospital, Bergen, Norway. Camilla.Tondel@k1.uib.no.
authors.forename: Camilla
authors.initials: C
authors.lastname: Tøndel
authors.affiliation: General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia. bojan.vujkovac@guest.arnes.si.
authors.forename: Bojan
authors.initials: B
authors.lastname: Vujkovac
authors.affiliation: Innere Klinik II, Katharinen Hospital Unna, Unna, Germany. f.weidemann@katharinen-hospital.de.
authors.forename: Frank
authors.initials: F
authors.lastname: Weidemann
authors.affiliation: Department of Paediatrics, Academic Medical Center, Amsterdam, The Netherlands. f.a.wijburg@amc.uva.nl.
authors.forename: Frits A
authors.initials: FA
authors.lastname: Wijburg
authors.affiliation: Department of Cardiology, Salford Royal Hospital NHS Foundation Trust, Manchester, UK. Peter.Woolfson@srft.nhs.uk.
authors.forename: Peter
authors.initials: P
authors.lastname: Woolfson
authors.affiliation: Department of Internal Medicine, Division Endocrinology and Metabolism, Academic Medical Center, PO Box 22660, Amsterdam, 1100 DD, The Netherlands. c.e.hollak@amc.uva.nl.
authors.forename: Carla E M
authors.initials: CE
authors.lastname: Hollak
mesh_terms: D000293:Adolescent; D018450:Disease Progression; D056947:Enzyme Replacement Therapy; D000795:Fabry Disease / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D017410:Practice Guidelines as Topic; D000519:alpha-Galactosidase / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D007527:Isoenzymes; D000519:alpha-Galactosidase; C459420:agalsidase beta